Peptron
Financials
Valuation Metrics
Peptron's Market Cap is ₩3.6T. At end of 2025 it was ₩5.9T. Ranked #131 of 2,421 in KR market (top 5%), #16 of 1,640 on KOSDAQ (top 1.0%), #9 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.60T KRW | KR#131/2,421 Sec#9/231 |
| Revenue | 6.00B KRW | KR#2,324/2,421 Sec#188/231 |
| Net Income | -20.53B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 167.98B KRW | KR#1,427/2,421 Sec#109/231 |
| Net Assets | 129.48B KRW | KR#1,240/2,421 Sec#96/231 |
| Employees | 112 | KR#1,557/2,421 Sec#121/231 |
| Value | ||
| P/B | 27.82x | KR#2,407/2,421 Sec#227/231 |
| P/S | 600.34x | KR#2,408/2,421 Sec#223/231 |
| FCF Yield | -0.64% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -15.86% | KR#2,036/2,421 Sec#156/231 |
| ROA | -12.22% | KR#2,148/2,421 Sec#164/231 |
| Op. Margin | -427.48% | KR#2,362/2,421 Sec#202/231 |
| Revenue Growth | 15.87% | KR#658/2,421 Sec#60/231 |
| Financial Health | ||
| Debt Ratio | 29.74% | KR#587/2,421 Sec#67/231 |
| Total Debt | 30.28B KRW | KR#1,224/2,421 Sec#94/231 |
| FCF | -23.08B KRW | KR#1,929/2,421 Sec#185/231 |
| Cash | 12.31B KRW | KR#1,569/2,421 Sec#129/231 |
| Current Ratio | 9.11x | KR#120/2,421 Sec#28/231 |
| Performance | ||
| 1Y Return | -46.63% | KR#1,983/2,421 Sec#175/231 |
| 1M Return | -16.89% | KR#2,276/2,421 Sec#200/231 |
| From 52W High | -60.64% | KR#1,882/2,421 Sec#146/231 |
| 1Y MDD | -73.16% | KR#2,116/2,421 Sec#186/231 |
| Trading | ||
| Volume | 80,225 shares | KR#890/2,421 Sec#89/231 |
| Trading Value | 12.22B KRW | KR#225/2,421 Sec#17/231 |
| Foreign Own. | 4.60% | KR#927/2,421 Sec#82/231 |
| Per Share | ||
| EPS | -881 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,553 KRW | KR#1,413/2,421 Sec#100/231 |
Company Info
Peptron, established in 1997 for biotechnology advanced material manufacturing and pharmaceutical R&D, was listed on KOSDAQ in 2015. The company develops pharmaceuticals based on peptide engineering and drug efficacy sustaining original technology, securing clinical trial and commercialization capabilities through GMP mass production facilities. With its SmartDepot technology, Peptron can develop various pharmaceuticals, accelerate its contract drug development and manufacturing business, and conduct research on metabolic disease treatments and anticancer drugs. The company is headquartered in Yuseong-gu, Daejeon.